Literature DB >> 3276729

Quantitative study of insulin secretion and clearance in normal and obese subjects.

K S Polonsky1, B D Given, L Hirsch, E T Shapiro, H Tillil, C Beebe, J A Galloway, B H Frank, T Karrison, E Van Cauter.   

Abstract

The secretion and hepatic extraction of insulin were compared in 14 normal volunteers and 15 obese subjects using a previously validated mathematical model of insulin secretion and rate constants for C-peptide derived from analysis of individual decay curves after intravenous bolus injections of biosynthetic human C-peptide. Insulin secretion rates were substantially higher than normal in the obese subjects after an overnight fast (86.7 +/- 7.1 vs. 50.9 +/- 4.8 pmol/m2 per min, P less than 0.001, mean +/- SEM), over a 24-h period on a mixed diet (279.6 +/- 24.2 vs. 145.8 +/- 8.8 nmol/m2 per 24 h, P less than 0.001), and during a hyperglycemic intravenous glucose infusion (102.2 +/- 10.8 vs. 57.2 +/- 2.8 nmol/m2 per 180 min, P less than 0.001). Linear regression analysis revealed a highly significant relationship between insulin secretion and body mass index. Basal hepatic insulin extraction was not significantly different in the normal and obese subjects (53.1 +/- 3.8 vs. 51.6 +/- 4.0%). In the normal subjects, fasting insulin did not correlate with basal hepatic insulin extraction, but a significant negative correlation between fasting insulin and hepatic insulin extraction was seen in obesity (r = -0.63, P less than 0.02). This finding reflected a higher extraction in the six obese subjects with fasting insulin levels within the range of the normal subjects than in the nine subjects with elevated fasting insulin concentrations (61 +/- 3 vs. 45 +/- 6%, P less than 0.05). During the hyperglycemic clamp, the insulin secretion rate increased to an average maximum of 6.2-fold over baseline in the normal subjects and 5.8-fold in the obese subjects. Over the same time, the peripheral insulin concentration increased 14.1-fold over baseline in the normals and 16.6-fold over baseline in the obese, indicating a reduction in the clearance of endogenously secreted insulin. Although the fall in insulin clearance tended to be greater in the obese subjects, the differences between the two groups were not statistically significant. Thus, under basal, fasting conditions and during ingestion of a mixed diet, the hyperinsulinemia of obesity results predominantly from increased insulin secretion. In patients with more marked basal hyperinsulinemia and during intense stimulation of insulin secretion, a reduction in insulin clearance may contribute to the greater increase in peripheral insulin concentrations that are characteristic of the obese state.+

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276729      PMCID: PMC329588          DOI: 10.1172/JCI113338

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Inverse relationship of metabolic clearance rate of insulin to body mass index.

Authors:  M B Davidson; M D Harris; C S Rosenberg
Journal:  Metabolism       Date:  1987-03       Impact factor: 8.694

2.  Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man.

Authors:  W Waldhäusl; P Bratusch-Marrain; S Gasic; A Korn; P Nowotny
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

3.  Effect of intraduodenal glucose administration on hepatic extraction of insulin in the anesthetized dog.

Authors:  M Kaden; P Harding; J B Field
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

4.  C-Peptide and insulin secretion in Pima Indians and Caucasians: constant fractional hepatic extraction over a wide range of insulin concentrations and in obesity.

Authors:  P J Savage; E V Flock; M E Mako; P M Blix; A H Rubenstein; P H Bennett
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

5.  Correlation of urinary excretion of C-peptide with the integrated concentration and secretion rate of insulin.

Authors:  M T Meistas; Z Zadik; S Margolis; A A Kowarski
Journal:  Diabetes       Date:  1981-08       Impact factor: 9.461

6.  Characterization of seven C-peptide antisera.

Authors:  O K Faber; C Binder; J Markussen; L G Heding; V K Naithani; H Kuzuya; P Blix; D L Horwitz; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

7.  Relation of body fat distribution to metabolic complications of obesity.

Authors:  A H Kissebah; N Vydelingum; R Murray; D J Evans; A J Hartz; R K Kalkhoff; P W Adams
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

8.  Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide. Study in obese and diabetic subjects.

Authors:  M T Meistas; M Rendell; S Margolis; A A Kowarski
Journal:  Diabetes       Date:  1982-05       Impact factor: 9.461

9.  Decreased insulin removal contributes to hyperinsulinemia in obesity.

Authors:  O K Faber; K Christensen; H Kehlet; S Madsbad; C Binder
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

10.  Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior.

Authors:  R P Eaton; R C Allen; D S Schade; K M Erickson; J Standefer
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  117 in total

Review 1.  Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.

Authors:  M K Cavaghan; D A Ehrmann; K S Polonsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  The medical risks of obesity.

Authors:  F Xavier Pi-Sunyer
Journal:  Obes Surg       Date:  2002-04       Impact factor: 4.129

3.  Insulin clearance is different in men and women.

Authors:  Michael D Jensen; Soren Nielsen; Nidhi Gupta; Rita Basu; Robert A Rizza
Journal:  Metabolism       Date:  2011-10-13       Impact factor: 8.694

4.  Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity.

Authors:  Leona Plum; Xiaosong Ma; Brigitte Hampel; Nina Balthasar; Roberto Coppari; Heike Münzberg; Marya Shanabrough; Denis Burdakov; Eva Rother; Ruth Janoschek; Jens Alber; Bengt F Belgardt; Linda Koch; Jost Seibler; Frieder Schwenk; Csaba Fekete; Akira Suzuki; Tak W Mak; Wilhelm Krone; Tamas L Horvath; Frances M Ashcroft; Jens C Brüning
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

5.  Quantitative and qualitative differences in basal and glucose- and arginine-stimulated insulin secretion in healthy subjects and different stages of NIDDM.

Authors:  K Ratheiser; W Reitgruber; M Komjati; P Bratusch-Marrain; H Vierhapper; W K Waldhäusl
Journal:  Acta Diabetol Lat       Date:  1990 Jul-Sep

Review 6.  Beta cell mass in diabetes: a realistic therapeutic target?

Authors:  J J Meier
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

7.  Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion.

Authors:  Howard Zisser; Eyal Dassau; Justin J Lee; Rebecca A Harvey; Wendy Bevier; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2015-04-21

8.  β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Authors:  Kevan C Herold; Sahar Usmani-Brown; Tara Ghazi; Jasmin Lebastchi; Craig A Beam; Melena D Bellin; Michel Ledizet; Jay M Sosenko; Jeffrey P Krischer; Jerry P Palmer
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

9.  Paradoxical inhibition of insulin secretion by glucose in non-insulin-dependent diabetic patients.

Authors:  M Linstow; K J Mikines; F Dela; H Galbo
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

10.  Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females.

Authors:  V Padmanabhan; A Veiga-Lopez; D H Abbott; S E Recabarren; C Herkimer
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.